Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) shot up 8.7% during mid-day trading on Monday . The company traded as high as $12.60 and last traded at $12.60. 222,079 shares were traded during mid-day trading, a decline of 71% from the average session volume of 759,327 shares. The stock had previously closed at $11.59.
Analyst Ratings Changes
A number of research firms recently issued reports on IMNM. Piper Sandler reduced their target price on Immunome from $27.00 to $23.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $29.00.
Check Out Our Latest Report on Immunome
Immunome Trading Up 10.5 %
The business's 50-day simple moving average is $13.63 and its two-hundred day simple moving average is $13.96. The company has a market capitalization of $769.24 million, a PE ratio of -1.67 and a beta of 1.82.
Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The firm had revenue of $2.36 million during the quarter, compared to analysts' expectations of $2.62 million. On average, analysts forecast that Immunome, Inc. will post -1.92 EPS for the current year.
Insider Transactions at Immunome
In related news, insider Jack Higgins sold 3,524 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the sale, the insider now owns 16,000 shares in the company, valued at $222,880. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Immunome news, insider Jack Higgins sold 3,524 shares of the firm's stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now owns 16,000 shares in the company, valued at approximately $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the company's stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the purchase, the director now directly owns 16,615 shares of the company's stock, valued at $231,613.10. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 8.60% of the company's stock.
Institutional Trading of Immunome
A number of large investors have recently added to or reduced their stakes in the business. Swiss National Bank acquired a new position in shares of Immunome during the 1st quarter worth $1,762,000. Sei Investments Co. acquired a new position in shares of Immunome in the 1st quarter valued at $469,000. Lord Abbett & CO. LLC acquired a new stake in shares of Immunome during the 1st quarter worth about $10,994,000. Vanguard Group Inc. increased its position in shares of Immunome by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company's stock worth $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of Immunome by 602.1% during the 1st quarter. Acadian Asset Management LLC now owns 133,438 shares of the company's stock worth $3,292,000 after purchasing an additional 114,433 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Further Reading
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
